logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Number of Files Under Consideration at pCPA Remains Low

January 13, 2022
-
Market Access News
-
Posted by MORSE - 4 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): December 2021 Trends and Insights

 

UPDATE & REQUEST FOR PARTICIPATION IN A SURVEY

MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. By analyzing quarterly vs. monthly data we expect to be able to identify important trends and provide useful insights to the market access community. We value our readers and would like to request your feedback in order to improve our content as we transition to this new format. It would be greatly appreciated if you could complete our 2 minute survey CLICK HERE.

Our next pCPA update will be published in April 2022.

 

December 2021 Highlights:

  • 5 products completed CADTH review
  • 2 products initiated pCPA negotiations
  • 6 negotiations were completed with an LOI
  • 1 negotiation was closed without an LOI
  • 0 files were closed without negotiation

 

Key Take-Aways:

  • The average time under pCPA consideration stays at 184, similar to last month’s high of 185 days. Seven files have been under consideration for more than 200 days, and four of those have surpassed 550 days. November and December have the lowest number of files under consideration that we saw in all of 2021.
  • The pCPA initiated 2 and completed/closed 7 negotiations in December, reducing the total number of active files to 40. The ratio of files under consideration relative to total volume continues to remain under 50%.
  • The pCPA concluded 6 negotiations with an LOI in December, and closed 1 negotiation without an agreement. Notably, all the completed negotiations were equal to or faster than average ranging from 48 to 146 days.
  • The volume of files under negotiation decreased to 40 in December, and the average days under negotiation returned to levels observed over the previous quarter. The number of files adjudicated by the pCPA rebounded from last month’s low, with a total of 7 files coming to conclusion.

 

Files Under pCPA Consideration*:

CADTH issued 5 new recommendations in December 2021 (26 files under pCPA consideration as of December 31st – up from 23 in November).

PRODUCT INDICATION SPONSOR Reimbursement Recommendation REC’N* DATE
Non-Oncology
Reblozyl (luspatercept) Myelodysplastic syndromes-associated anemia Celgene Inc. Conditional Reimbursement 2021-12-07
Opsynvi (macitentan and tadalafil) Pulmonary arterial hypertension Janssen Inc. Conditional Reimbursement 2021-12-14
Emgality (galcanezumab) Prevention of migraine Eli Lilly Canada Inc. Conditional Reimbursement 2021-12-15
Oncology
Keytruda (pembrolizumab) Esophageal carcinoma, gastroesophageal junction adenocarcinoma Merck Canada Inc. Conditional Reimbursement 2021-12-02
Brukinsa (zanubrutinib) Waldenström’s macroglobulinemia BeiGene, Ltd. Conditional Reimbursement 2021-12-01

Note: MORSE defines “Rec’n date” as the time of final recommendation issued to sponsor and drug plans’, and the ‘Time to Initiate’ as the time between ‘final recommendation issued to sponsor and drug plans’ and ‘pCPA Engagement Letter Issued’.



*Note: that files that initiated pCPA negotiation prior to receiving a CADTH recommendation were excluded from the under-consideration timeline analysis

Signals Decoded:

 

The average time under pCPA consideration stays at 184, similar to last month’s high of 185 days. Seven files have been under consideration for more than 200 days, and four of those have surpassed 550 days. The number of files under consideration increased only slightly after 5 new CADTH recommendations and 2 new pCPA negotiation initiations. November and December have the lowest number of files under consideration that we saw in all of 2021

 

Negotiation Initiation:

The pCPA initiated 2 new negotiations in December, bringing the number of active negotiations to 40 (as of December 31st), down from 45 in November.

PRODUCT INDICATION SPONSOR INITIATE DATE TTI*
Non-Oncology
MAR-Trientine (Trientine Hydrochloride) Wilson’s Disease Marcan Pharmaceuticals Inc. 2021-12-07 26
Oncology
Inrebic (fedratinib) Myelofibrosis Celgene Inc. 2021-12-21 202

*Time to Initiation (TTI) – Time between ‘final recommendation issued to sponsor and drug plans’ and ‘pCPA Engagement Letter Issued’

 

Signals Decoded:

TThe pCPA initiated 2 and completed/closed 7 negotiations in December, reducing the total number of active files to 40. MAR-Trientine (Trientine Hydrochloride), a rare disease drug, was initiated after 26 days under consideration. The ratio of files under consideration relative to total volume continues to remain under 50%.

 

Completed Negotiations:

The pCPA completed 6 negotiations with a Letter of Intent (LOI) in December 2021, up from 3 in November.

PRODUCT INDICATION Sponsor Status LOI DATE TTN*
Non-Oncology
Ajovy (fremanezumab) Migraine Teva Canada Inc. Completed 2021-12-03 140
Ilumya (tildrakizumab) Psoriasis, moderate to severe plaque Sun Pharma Canada Inc. Completed 2021-12-20 94
Oncology
Alunbrig (Brigatinib) Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Takeda Canada Inc. Completed 2021-12-16 48
Bavencio (Avelumab) Urothelial Carcinoma (UC) EMD Serono Completed 2021-12-15 146
Polivy (Polatuzumab Vedotin) Relapsed or refractory diffuse large B-cell lymphoma Hoffmann-La Roche Limited Completed 2021-12-01 133
Venclexta (Venetoclax, in combo with azacitidine ) Acute myeloid leukemia AbbVie Corporation Completed 2021-12-06 68

* TTN = Time to Negotiate in calendar days

Closed Negotiations:

The pCPA closed 1 negotiation without an LOI in December 2021.

PRODUCT INDICATION Sponsor Status Close Date TTC*
Non-Oncology
Aimovig (erenumab) Migraine Novartis Pharmaceuticals Canada Inc Closed 2021-12-13 322

Not Negotiated:

The pCPA did not decline any negotiations in December 2021.

 

Signals Decoded:

The pCPA concluded 6 negotiations with an LOI in December, and closed 1 negotiation without an agreement. Notably, all the completed negotiations were equal to or faster than average ranging from 48 to 146 days. Aimovig (erenumab) for migraine closed without an LOI after 322 days of negotiation, while another migraine drug Ajovy (fremanezumab) reached an agreement after 140 days.

 

Signals Decoded:

The volume of files under negotiation decreased to 40 in December, and the average days under negotiation returned to levels observed over the previous quarter.

Reblozyl (luspatercept) for anemia associated with beta-thalassemia surpassed 200 days under consideration by pCPA in December, bringing the number of files under consideration for greater than 6 months to 7. CADTH issued a recommendation for the same drug in December for another anemia indication, which may be impacting pCPA’s approach to the file.

The number of files adjudicated by the pCPA rebounded from last month’s low, with a total of 7 files coming to conclusion.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
MORSE Consulting Releases its Fifth Annual pCPA Year in Review Infographic (2021 Edition)
NEXT POST →
Season’s Greetings from MORSE Consulting

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Number of Files Under Consideration at pCPA Remains Low